UNSPSC 51351616: Promestriene

This classification denotes a therapeutic estrogen with the molecular formula C22H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GXM4PER6WZ, chemically known as 17beta-methoxy-3-propoxyestra-1,3,5(10)-triene but generally known as promestriene, which bears US NIH Compound Identifier 71717. European Medicines Agency schedules Promestriene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10087MIG.

UNSPSC 51351616 Promestriene is a Commodity code capturing generic pharmaceutical products and over-the-counter medications procured by state and local health systems, purchasing cooperatives, and government facility networks. State and local buyers under this code are sourcing branded and generic pharmaceuticals, OTC products, and specialty medications for distribution across public health departments, correctional facilities, state hospitals, and shared cooperative purchasing networks. Procurement typically requires vendors to maintain relationships with authorized pharmaceutical wholesalers, comply with cGMP and Drug Supply Chain Security Act standards, provide NDC-coded product catalogs with pricing flexibility across multiple net-price formats, and maintain substantial liability insurance. The issuing bodies are primarily state health agencies and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions to negotiate volume pricing and standardized supply agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities including Oregon. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes price competitiveness (75 percent of evaluation weight), EDI capability, compliance with administrative fee formatting, and flat or net-price structures. The contract term is two years for new responders with optional extensions, effective July 1, 2026, and all products must be available in the marketplace by May 15, 2026. No specific budget range or award value is disclosed; vendors should anticipate a 3 percent administrative fee on all purchases and performance penalties of $200 to $1,500 per violation for reporting delays or onboarding failures.